How are we making this vision a reality?
The answer is that we are developing and testing products that deliver nicotine without the harmful smoke of cigarettes – yet that consumers will find satisfying. Since 2008, we’ve invested over USD 4.5 billion, employing over 400 world-class scientists, engineers, and technicians.
We’re already making these new products available. Around five million consumers have switched to the first of our smoke-free products.
Our priority is clear – to switch, as quickly as possible, hundreds of millions of adult smokers to less harmful alternatives than continued smoking.
These new products are only intended for adult smokers and not for those who have never smoked or are former smokers.
Over a billion people will smoke in 2025 according to the World Health Organization, despite campaigns to quit smoking. There is no substitute for quitting, but we believe we can also have a big impact on public health by promoting alternatives to smoking cigarettes.
We are making major investments in alternative products that adult smokers will find satisfying but offer less risk than cigarettes. We want the millions of men and women who smoke to have the opportunity to learn about and use these potentially less harmful alternatives.
We are developing new products with the potential to replace cigarettes. We do this by applying technologies that do not require burning (or combustion) and that produce a flavorful and satisfying nicotine-containing vapor (instead of smoke).
Our current product portfolio contains two products that heat tobacco to produce a vapor and two that use liquid nicotine to produce a vapor. We are designing all these breakthrough products to appeal to adult smokers so that they switch to them.
Our entire R&D organization is focused on developing satisfying products that are less harmful than cigarettes for adult smokers around the world.
We have set high standards for ourselves and welcome visits to our facilities to see what we do. In our laboratories you would see the same expertise and rigor that you would expect to find in leading pharmaceutical companies.
Our methodologies and findings are shared with scientific experts and regulators through publication in peer-reviewed scientific journals, presentations at scientific conferences, and PMIScience.com. All of our clinical studies are registered on ClinicalTrials.gov.
In addition, we invite independent verification of our scientific results.